BFS
VRTX icon

Bare Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bare Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.91K Sell
11
-8
-42% -$3.73K ﹤0.01% 653
2025
Q4 		$8.61K Sell
19
-6
-24% -$2.59K ﹤0.01% 298
2025
Q3 		$9.79K Buy
25
+4
+19% +$1.67K ﹤0.01% 243
2025
Q2 		$9.35K Buy
21
+18
+600% +$8.29K ﹤0.01% 196
2025
Q1 		$1.45K Buy
+3
New +$1.4K ﹤0.01% 412

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bare Financial Services's VRTX Position: Q1 2026 in Review

Bare Financial Services reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q1 2026, selling an estimated $3.73K and leaving 11 shares worth $4.91K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

Bare Financial Services first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $9.79K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bare Financial Services held 11 shares of Vertex Pharmaceuticals worth $4.91K as of Q1 2026.
  • Bare Financial Services sold 8 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.73K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Bare Financial Services's portfolio in Q1 2026, its #653 holding.
  • Bare Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Bare Financial Services's Vertex Pharmaceuticals position peaked at $9.79K in Q3 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bare Financial Services's 13F filing for Q1 2026, filed 14 May 2026.